Good metabolic control using tacrolimus-based immunosuppressants in primary cadaveric renal transplantation in Chinese - a preliminary report
Publication in refereed journal

Times Cited
Web of Science3WOS source URL (as at 13/09/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractMetabolic complications are common with tacrolimus therapy. Recent evidence suggests that there is ethnical variability in the side-effect profile of tacrolimus. We performed an open-label study to examine the metabolic profile of tacrolimus-based immunosuppressive therapy in 10 consecutive adult Chinese patients after cadaveric renal transplantation. One case withdrew because of parvovirus infection. The mean age of the remaining nine cases was 33 +/- 2.9 yr. Mean tacrolimus whole blood trough level at 0 and 12 months were 11.4 +/- 1.8 and 7.0 +/- 0.7 ng/mL, respectively. The dosage at corresponding time points were 0.31 +/- 0.001 and 0.10 +/- 0.003 mg/kg, respectively. We found no difference in lipid profile, blood pressure control, and most importantly, fasting glucose level, before and I yr after tacrolimus therapy. Standard 75-g oral glucose tolerance test and whole blood HbA1c level were normal in all patients. Our preliminary data suggest good short-term safety among Chinese renal transplantation recipients after tacrolimus-based immunosuppressants, with a very low incidence of hyperglycemia, hypertension and dyslipidemia. The long-term implications and the underlying explanation for this ethnical difference require further investigations.
All Author(s) ListChow KM, Szeto CC, Li PKT
Journal nameClinical Transplantation
Volume Number16
Issue Number1
Pages39 - 42
LanguagesEnglish-United Kingdom
KeywordsChinese; metabolic control; post-transplant diabetes mellitus; tacrolimus
Web of Science Subject CategoriesSurgery; SURGERY; Transplantation; TRANSPLANTATION

Last updated on 2021-14-09 at 00:41